Drug Trial Radar · NCT05761223
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
151
Planned (sponsor's estimate)
Start
Dec 13, 2023
Primary completion
Jun 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- 1ST Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.
Conditions
- Advanced Solid Tumor
Interventions
Phase Ia dose-escalation part of FB849 MonotherapyDrug
At a given level dose once daily
Phase Ib dose-expansion of FB849 monotherapyDrug
At recommended dose for expansion cohort once daily
Phase IIb dose-escalation part of FB849 in Combination with PembrolizumabDrug
At recommended dose for expansion cohort once daily in combination with pembrolizumab
Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)Drug
At recommended dose for expansion cohort once daily in combination with pembrolizumab
Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)Drug
At recommended dose for expansion cohort once daily in combination with pembrolizumab
Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)Drug
At recommended dose for expansion cohort once daily in combination with pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of FB849 and to identify maximum tolerated dose (MTD)/ recommended Phase II dose (RP2D) and dosing schedule of FB849 in subjects with advanced solid tumorsTime frame: DLT Assessment at the end of Cycle 1(each cycle is 21 days.)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio · Recruiting
Mary Crowley Cancer Research Center
Dallas, Texas · Recruiting
NEXT Oncology San Antonio
San Antonio, Texas · Recruiting
Next Oncology Virginia
Fairfax, Virginia · Recruiting
Summit Cancer Centers - Spokane Valley
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.